Chronic pain patients consuming hemp-derived cannabidiol, or CBD, on a daily basis for eight weeks reported a decrease in the opioid medications they needed, a new study reports.
“This is a prospective, single-arm cohort study for the potential role of cannabinoids as an alternative for opioids,” the paper states. “The results indicate that using the CBD-rich extract enabled our patients to reduce or eliminate opioids with significant improvement in their quality of life indices.”
The study, published this month in Postgraduate Medicine, sheds new light on the potential benefits of CBD extracted from hemp, a crop that became federally legal under the 2018 Farm Bill, although the Food and Drug Administration has yet to issue finalized guidelines that would allow CBD to be sold in dietary supplements and food products.
Researchers recruited 131 patients who obtain their care from the same pain clinic; 97 completed the eight-week follow-up period. All had been diagnosed with chronic pain and were taking opioid medications for relief.
For the study, participants were given a 60-count bottle of hemp-derived, CBD-rich soft gels. Each gel, according to the study, contained 15.7 mg CBD, 0.5 mg THC, 0.3 mg cannabidivarin, 0.9 mg cannabidiolic acid, 0.8 mg cannabichrome, and less than 1 percent of a botanical terpene blend. Nearly all (91) took two gel caps a day, totaling 30 mg of CBD; three participants opted not to use the hemp extract at all.
“CBD could significantly reduce opioid use and improve chronic pain and sleep quality among patients who are currently using opioids for pain management.”
Researchers asked participants to complete a series of questionnaires to access various factors at the onset of the study, at the four-week mark and at the eight-week point. Among them: their pain intensity level, how much their pain disrupted their lives, the quality of their sleep and how willing they were to cut back on opioids.
Of the total 94 participants who took CBD regularly, 50 reported they were able to reduce opioid medications at week 8. The authors also note: “Additional reductions in polypharmacy on the medication receipt were noted; six participants reported reducing or eliminating their anxiety medications, and four participants reported reducing or eliminating their sleep medication.”
Overall, 89 participants reported their quality of life had improved over the study period. Two measures changed significantly: patients’ self-rating of sleep quality and pain intensity and interference.
At baseline, the study’s authors calculated respondents’ scores regarding sleep quality to an average of 12.09—the higher the score, the poorer the quality of sleep. At the four-week and eight-week check-in points, the score decreased to 10.7 and 10.3, respectively. Similarly, another scale the authors used to measure pain and how it interferes with the enjoyment of life found the mean score value change from 6.5 at baseline to 5.9 at week 4 and 5.7 at week 8.
“The results of this study suggest that using CBD-rich hemp extract oil may help reduce opioid use and improve quality of life, specifically in regards to pain and sleep, among chronic pain patients,” the study concludes. “This is consistent with emerging literature on the topic, which has concluded that CBD is an effective analgesic, and one that helps reduce barriers to opioid reduction, such as physiological withdrawal symptoms.”
In an interview with Appalachian News Express, the study’s lead author Alex Capano said that outside of survey studies, her research is “the largest study on the use of CBD to reduce the use of opioids in the treatment of chronic pain.”
“It’s also the first study on CBD and opioid reduction to identify key data points, such as hemp extract doses, delivery method, and specific cannabinoid content,” she continued. “Most participants used a relatively low dose of 30mg of CBD per day, whereas other studies on CBD have tested very large doses, 10x or 20x that amount. Lower doses of CBD mean reduced risk of side effects and improved outcomes.”
Dogs Are Being Exposed To Marijuana Through Human Poop And Pet Owners Should Beware, Study Finds
A word of caution to dog owners: apparently some canines are getting intoxicated off marijuana by eating the feces of people who’ve consumed cannabis, according to a new study.
Dogs are natural scavengers, and so the instinct to eat poop—while gross—is just a fact of life. But a team of Australian researchers found that, in some cases, that instinct can become dangerous, warranting the attention of puppy parents.
The study, published in the Australian Veterinary Journal, looked at 15 cases of confirmed THC toxicosis in dogs who were suspected of, or observed to have, ingested human feces in Melbourne from 2011-2020.
The dogs presented symptoms of incoordination, dilated pupils, urinary incontinence and stupor. Urine tests from eight of the dogs showed THC metabolites in their system.
However, study author Clara Lauinger told Marijuana Moment that this shouldn’t necessarily be taken to mean that any level of THC is toxic in dogs.
“The animals in my study had ingested an unknown quantity of feces that contained an unknown concentration of THC and so one would assume this concentration would be at a level that clearly caused toxicity,” she wrote in an email. “However this does not mean that all THC ingestions can lead to toxicity.”
In fact, there are other studies where animals were administered a controlled dosage of THC and “not a single one of them displayed any adverse effects that we might see with toxicity,” she said.
“There are so so many anecdotal reports of the huge benefits that THC administration has on animals, albeit reports are from owners perception rather than peer reviewed research, but this does not mean the industry should disparage THC as a therapeutic agent,” Lauinger said.
Most of the dogs in her new study apparently ate the poop at local parks, while others ingested it at the beach, camp sites and walking trails.
“All dogs survived to discharge. Ingestion of human feces containing THC may lead to marijuana toxicosis in dogs,” the study states. “Veterinary staff and owners should be attentive in regard to using appropriate hygiene measures when managing these dogs.”
The authors said that there are a number of reasons that a dog might eat poop—or, put scientifically, engage in coprophagy. But they floated one possibility for the marijuana-specific feces-eating trend: “It is possible that the presence of marijuana in feces increases its attractiveness for ingestion by altering its scent, texture and/or taste.”
Also, while this study is limited to data on about two dozen dogs in one city of Australia, the authors also said that the habit “might be more common than what owners report,” pointing to Google search results from people reporting a dog ate feces and exhibited signs of lethargy.
The idea of dogs getting high off THC-containing human waste might seem like a stretch on its own, but the study also explains that canines have more cannabinoid receptors than humans, “making dogs more sensitive to the effects of THC.”
“In conclusion, this case series suggests that ingestion of feces produced by a human marijuana user may lead to signs of marijuana toxicosis,” the researchers said. “Clinical signs of toxicosis were similar to those previously reported for dogs with conrmed marijuana toxicosis though gastrointestinal signs were not the most common feature despite coprophagy.”
“Veterinary staff and owners should be mindful of this exposure source to ensure appropriate hygiene measures are taken when managing these dogs,” the study says.
Lauinger said that there “needs to be an industrywide understanding of the fact that there are so many different strains of cannabis and each of these strains has different cannabinoid profiles that have possible potential for beneficial therapeutic effects.”
“These strains could be researched with a focus on what ones are suitable for animals and at what dose rather than blanketing all strains as being toxic,” she said. “I hope the public can be patient and also get behind us researching the dosing more.”
While there are clear concerns about dogs ingesting excess levels of THC, studies have found promising results when it comes to the therapeutic potential of other cannabinoids like CBD for pets.
For example, dogs with epilepsy experience considerably fewer seizures when treated with CBD oil, a study published in the journal Pet Behaviour Science in 2019 found.
The prior year, a separate study determined that CBD can alleviate the symptoms of osteoarthritis in dogs.
The Food and Drug Administration (FDA), for its part, has repeatedly warned pet owners about using CBD to treat firework-related anxiety in pets around the July 4 holiday.
“You should be aware that FDA has NOT evaluated these products and can’t say whether they are safe or effective, how they are manufactured, or whether they contain CBD,” the agency said this year.
Photo courtesy of Pexels.
Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds
The use of psychedelics like LSD, psilocybin, mescaline and DMT is associated with a significant decrease in illicit opioid consumption, according to a new study.
Researchers looked at data from “three harmonized prospective cohorts of community-recruited” people with substance misuse disorders. A total of 3,813 individuals were involved, including 1,093 who reported illicit opioid consumption and 229 who said they’d used psychedelics in the past six months.
“Recent psychedelic use was associated with 55% reduced odds of daily opioid use,” the Vancouver-based study, published last week in the Journal of International Drug Policy, found.
While there have been numerous studies connecting legal marijuana access to reduced opioid use and fewer overdose deaths, this is “the first longitudinal study to link psychedelic use with lower daily opioid use,” the paper says.
“Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” the study states. “While confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.”
While there’s not a clear explanation for the trend—and the researchers urged additional studies—psychedelics like psilocybin and MDMA have been touted as potentially powerful tools in mental health treatment, effectively treating conditions like severe depression, post-traumatic stress disorder and addiction.
“These findings align with growing evidence demonstrating that psychedelic use may be associated with detectable reductions in subsequent opioid use, and warrant further research on psychedelics for opioid and other substance use disorders,” the study’s lead author, Elena Argento of the University of British Columbia, told Marijuana Moment.
“This study found naturalistic psychedelic use to be independently associated with a significantly reduced odds of subsequent daily illicit opioid use among a community-based sample of [people who use drugs],” the study concluded. “More research with controlled trials and longer-term follow-up is required to elucidate the therapeutic potential of psychedelics to augment existing interventions for substance use disorders, including among more diverse populations. Additional qualitative studies would also provide opportunities to improve understanding of the possible psycho-social mechanisms underpinning psychedelic experiences.”
Another recent study found that when people use cannabis together with psychedelics, it was “associated with higher scores of mystical-type experience, ego-dissolution and visual alterations.”
With respect to marijuana alone, a study published earlier this year found that cannabis use is associated with significant reductions in dependence on opioids and other prescription drugs, as well as an increase in quality of life
Another study released last year determined that states with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to prohibition states.
Marijuana Legalization In Canada Did Not Result In Increased Traffic Injuries, Study Finds
Canada’s move to legalize marijuana did not result in increased traffic injuries, a new study has found.
In a paper published in the journal Drug and Alcohol Dependence, researchers said they sought to investigate claims that establishing the cannabis legalization law, which took effect in October 2018, would make roads less safe, as prohibitionists frequently argue.
But after analyzing Ontario and Alberta emergency department data from April 2015 to December 2019, however, they couldn’t find any evidence to support that hypothesis.
“Implementation of the Cannabis Act was not associated with evidence of significant post-legalization changes in traffic-injury [emergency department] visits in Ontario or Alberta among all drivers or youth drivers, in particular,” the study states.
“Legalization not associated with changes in traffic injuries in all drivers or youth drivers.”
That’s despite the fact that “worldwide momentum toward legalization of recreational cannabis use has raised a common concern that such policies might increase cannabis-impaired driving and consequent traffic-related harms, especially among youth.”
The study’s lead author, Russ Callaghan, said in a press release that his team’s results “show no evidence that legalization was associated with significant changes in emergency department traffic-injury presentations.”
The researcher admitted that the outcome of the study is “somewhat surprising,” adding that he “predicted that legalization would increase cannabis use and cannabis-impaired driving in the population, and that this pattern would lead to increases in traffic-injury presentations to emergency departments.”
“It is possible that our results may be due to the deterrent effects of stricter federal legislation, such as Bill C-46, coming into force shortly after cannabis legalization,” he said, referring to a separate impaired driving bill. “These new traffic-safety laws imposed more severe penalties for impaired driving due to cannabis, alcohol, and combined cannabis and alcohol use.”
While Callaghan said he wasn’t expecting the results that his team ended up with, there is a body of existing research that’s also challenged the idea that legalization leads to increased traffic risks.
A U.S. congressional research body said in a 2019 report that concerns expressed by lawmakers that cannabis legalization will make the roads more dangerous might not be totally founded. In fact, the experts tasked by the House and Senate with looking into the issue found that evidence about cannabis’s ability to impair driving is currently inconclusive.
Other researchers have found on several occasions that traffic fatalities do not increase after a state legalizes marijuana.
A study published in the Journal of the American Medical Association late last year found that small doses of CBD appear to have no significant impact on driving, whereas comparable doses of THC were associated with short-term impairment “modest in magnitude and similar to that seen in drivers with a 0.05%” blood alcohol concentration.
In any case, House-approved report language related to funding for the Departments of Transportation, and Housing and Urban Development addresses drug-impaired driving from substances such as marijuana and urges the National Highway Traffic Safety Administration to take steps to address the issue.